Picture loading failed.

Anti-CD6 therapeutic antibody (Pre-made Itolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Itolizumab (INN, trade name Alzumab) is a ��first in class�� humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-284-1mg 1mg 3090
GMP-Bios-ab-284-10mg 10mg 21890
GMP-Bios-ab-284-100mg 100mg 148000
GMP-Bios-ab-284-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD6 therapeutic antibody (Pre-made Itolizumab biosimilar,Whole mAb)
INN Name Itolizumab
TargetCD6
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesCenter of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium
Conditions ApprovedPlaque psoriasis
Conditions ActiveGraft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis
Conditions DiscontinuedAutoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis
Development Techna